These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 18678855)

  • 41. N-acetylcysteine in the prevention of radiocontrast-induced nephropathy.
    Fishbane S; Durham JH; Marzo K; Rudnick M
    J Am Soc Nephrol; 2004 Feb; 15(2):251-60. PubMed ID: 14747371
    [TBL] [Abstract][Full Text] [Related]  

  • 42. N-acetylcysteine and contrast-induced nephropathy.
    Aguiar-Souto P; Valero-González S; Domínguez JF
    N Engl J Med; 2006 Oct; 355(14):1497-8; author reply 1499-500. PubMed ID: 17021328
    [No Abstract]   [Full Text] [Related]  

  • 43. N-Acetylcysteine in nephrology; contrast nephropathy and beyond.
    Tepel M; Zidek W
    Curr Opin Nephrol Hypertens; 2004 Nov; 13(6):649-54. PubMed ID: 15483456
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevention of contrast-induced nephropathy: an overview.
    Ellis JH; Cohan RH
    Radiol Clin North Am; 2009 Sep; 47(5):801-11, v. PubMed ID: 19744595
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis.
    Nallamothu BK; Shojania KG; Saint S; Hofer TP; Humes HD; Moscucci M; Bates ER
    Am J Med; 2004 Dec; 117(12):938-47. PubMed ID: 15629733
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Does N-acetylcysteine reduce the incidence of contrast-induced nephropathy and clinical events in patients undergoing primary angioplasty for acute myocardial infarction?
    Tanaka A; Suzuki Y; Suzuki N; Hirai T; Yasuda N; Miki K; Fujita M; Tanaka T
    Intern Med; 2011; 50(7):673-7. PubMed ID: 21467697
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A review of contemporary prevention strategies for radiocontrast nephropathy: a focus on fenoldopam and N-acetylcysteine.
    Lepor NE
    Rev Cardiovasc Med; 2003; 4 Suppl 1():S15-20. PubMed ID: 12556733
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prophylaxis of contrast material-induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study.
    Huber W; Eckel F; Hennig M; Rosenbrock H; Wacker A; Saur D; Sennefelder A; Hennico R; Schenk C; Meining A; Schmelz R; Fritsch R; Weiss W; Hamar P; Heemann U; Schmid RM
    Radiology; 2006 Jun; 239(3):793-804. PubMed ID: 16714461
    [TBL] [Abstract][Full Text] [Related]  

  • 49. N-acetylcysteine for prevention of radiographic contrast material-induced nephropathy: is the intravenous route best?
    Shalansky SJ; Vu T; Pate GE; Levin A; Humphries KH; Webb JG
    Pharmacotherapy; 2005 Aug; 25(8):1095-103. PubMed ID: 16207100
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Systematic review of the impact of N-acetylcysteine on contrast nephropathy.
    Pannu N; Manns B; Lee H; Tonelli M
    Kidney Int; 2004 Apr; 65(4):1366-74. PubMed ID: 15086476
    [TBL] [Abstract][Full Text] [Related]  

  • 51. N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials.
    Kshirsagar AV; Poole C; Mottl A; Shoham D; Franceschini N; Tudor G; Agrawal M; Denu-Ciocca C; Magnus Ohman E; Finn WF
    J Am Soc Nephrol; 2004 Mar; 15(3):761-9. PubMed ID: 14978179
    [TBL] [Abstract][Full Text] [Related]  

  • 52. N-acetylcysteine for prevention of radiocontrast induced nephrotoxicity: the importance of dose and route of administration.
    Shalansky SJ; Pate GE; Levin A; Webb JG
    Heart; 2005 Aug; 91(8):997-9. PubMed ID: 16020580
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [ Use of N-acetylcysteine for the prevention of contrast-induced nephropathy in rats].
    Inci MF; Salk I; Solak O; Vurdem UE; Inci R
    Actas Urol Esp; 2012 Apr; 36(4):210-5. PubMed ID: 22548227
    [No Abstract]   [Full Text] [Related]  

  • 54. Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial.
    Ozcan EE; Guneri S; Akdeniz B; Akyildiz IZ; Senaslan O; Baris N; Aslan O; Badak O
    Am Heart J; 2007 Sep; 154(3):539-44. PubMed ID: 17719303
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Contrast nephropathy after coronary angiography.
    Gami AS; Garovic VD
    Mayo Clin Proc; 2004 Feb; 79(2):211-9. PubMed ID: 14959916
    [TBL] [Abstract][Full Text] [Related]  

  • 56. N-acetylcysteine versus ascorbic acid or N-acetylcysteine plus ascorbic acid in preventing contrast-induced nephropathy: A meta-analysis.
    Feng Y; Huang X; Li L; Chen Z
    Nephrology (Carlton); 2018 Jun; 23(6):530-538. PubMed ID: 28452187
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury.
    Drager LF; Andrade L; Barros de Toledo JF; Laurindo FR; Machado César LA; Seguro AC
    Nephrol Dial Transplant; 2004 Jul; 19(7):1803-7. PubMed ID: 15128882
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In search of an algorithm to prevent acute kidney injury.
    Dauerman HL
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1125-7. PubMed ID: 19926055
    [No Abstract]   [Full Text] [Related]  

  • 59. Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics.
    Coyle LC; Rodriguez A; Jeschke RE; Simon-Lee A; Abbott KC; Taylor AJ
    Am Heart J; 2006 May; 151(5):1032.e9-12. PubMed ID: 16644332
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The third strike.
    Brinker JA
    Catheter Cardiovasc Interv; 2002 Nov; 57(3):284-5. PubMed ID: 12410498
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.